“We are very pleased that the FDA has approved the heart failure label extension of Injectafer®, and congratulate our partner on this milestone”, said Hervé Gisserot, General Manager of CSL Vifor. “Every second patient with chronic heart failure suffers from iron deficiency, with a significant number of patients either not being diagnosed or inadequately treated for iron deficiency. We are confident that Injectafer® can make a meaningful contribution to achieve key therapeutic goals in the treatment of these patients.”
Article and further references here: LINK
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$255.31 |
Change
-2.070(0.80%) |
Mkt cap ! $123.6B | |||
| Open | High | Low | Value | Volume |
| $256.32 | $256.50 | $252.60 | $171.9M | 674.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6 | $255.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $255.83 | 104 | 1 |
View Market Depth
| Last trade - 16.14pm 21/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |